Is DABUR a good buy for long term?
The long-term outlook for Dabur India suggests potential growth, with analysts projecting a target of Rs 591.8 by fiscal year 2028, contingent on sustained earnings growth and potential sector multiple re-ratings. For a 12-month horizon, the base case prediction is Rs 486.2, representing roughly 15% upside from recent prices. However, success depends on factors like rural demand recovery, premiumisation, and effective cost management. As with any investment, this is a forecast rather than a guaranteed return, and investors should be mindful of risks like raw material price spikes and sector competition.
Related FAQs
Dr Lal PathLabs provides diagnostic and healthcare testing services internationally across 23 countries, operating through an extensive network that includes more than 150 partner hospitals and reference laboratories.
Whether Dabur is a good stock to buy depends on your investment horizon and risk tolerance. With a base case target of Rs 486.2 for 2026 and long-term potential reaching Rs 591.
Yes, Dabur is a profitable company. For the fourth quarter of the 2025-26 fiscal year, Dabur India reported a consolidated net profit of Rs 362 Crore, which was a 16% increase from Rs 312.7 Crore in the previous year.
Dabur maintains a documented commitment to ethical conduct through its Code of Conduct, which applies to all directors and employees.
No, Dabur India is not debt-free. As of March 2026, the company's current portion of total debt was 10.902 billion. While the company has actively managed its liabilities over the past five years—with debt levels fluctuating between a low of 4.